The abstract is read at the publisher; the summary is JClub's.
Androgen receptor signaling is linked to suppressed adaptive anticancer immunity, and AR inhibition is shown in preclinical cancer models to enhance T cell function and sensitize tumors to immune checkpoint blockade.
- Why it matters: Sex-based differences in cancer incidence and mortality are implicated to involve AR signaling, and reconciling preclinical promise with failed Phase 3 prostate cancer trials is a key translational gap.
- What they did: The work reviews evidence from preclinical studies across multiple cancer types and discusses why Phase 3 trials in prostate cancer combining AR suppression with immune checkpoint blockade failed to show benefit.
- The result: The synthesis proposes trial-design strategies to better integrate AR suppression with immunotherapy, aiming to optimize translation of emerging mechanistic insights into clinical testing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.